---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-22-000031"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:55:52.531243+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs Q3 net loss $24.6M; cash $185.1M; SL-172154 trial enrollment complete

## Summary
- Net loss of $24.6M ($0.58/share) vs $17.4M ($0.41/share) in Q3 2021, driven by higher R&D and G&A costs.
- Cash and investments $185.1M as of Sep 30, 2022, down from $268.8M at Dec 31, 2021; cash runway into H2 2024.
- Completed enrollment in Phase 1 monotherapy dose-escalation of SL-172154 in platinum-resistant ovarian cancer; final data expected midyear 2023.
- First patient dosed in Phase 1B combination trial of SL-172154 with liposomal doxorubicin in ovarian cancer; initial data expected midyear 2023.
- R&D expenses $18.9M (up 25% YoY); G&A $6.6M (up 53% YoY, including $1.4M litigation settlement).

## SEC filing metadata
- accession: 0001680367-22-000031
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036722000031/0001680367-22-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036722000031/sttk-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-22-000031
- JSON: https://secwatch.observer/filing/0001680367-22-000031.json
- Plain text: https://secwatch.observer/filing/0001680367-22-000031.txt

## Key facts
- Earnings Releases
  Shattuck Labs, Inc. reported the quarter ended September 30, 2022 results: net income ($0.58) per basic and diluted share, EPS $0.58 per basic and diluted share.
  - Period: the quarter ended September 30, 2022
  - Net income: ($0.58) per basic and diluted share
  - EPS: $0.58 per basic and diluted share
  - Result: reported results
  source text: Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680367/000168036722000031/0001680367-22-000031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.